NCT04180046

Utility of Primary Glioblastoma Cell Lines

Status unknown Last updated 12 April 2021

What this trial tests

trial in Tumor in 10 participants. Status unknown.

Timeline

26 June 2019

Primary endpoint
26 June 2019

30 December 2021

Quick facts

Lead sponsor	Neuromed IRCCS
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	10
Start date	26 June 2019
Primary completion	26 June 2019
Estimated completion	30 December 2021
Sites	1 location across Italy

Conditions studied

• Tumor — all drugs for Tumor →
• Brain Tumor — all drugs for Brain Tumor →

Sponsor

Neuromed IRCCS

Who can join

Eligibility, any sex, with Tumor or Brain Tumor. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

In this study, the characterization of human malignant glioma cell lines is described. After mechanical and enzymatic digestion of glioblastoma human biopsies from Neuromed IRCCS Neurosurgery patients, the investigators analyzed the established cell lines by immunohistochemistry. The investigators have already characterized 10 cell lines and results revealed that not all cell lines are positive for glial fibrillary acidic protein (GFAP), but only one was positive: the so-called COGI cell line. Moreover, the expression of Isocitrate Dehydrogenase 1(IDH1) and alpha thalassemia/mental retardation syndrome X-linked protein (ATRX) was investigated in all established cell lines. COGI cell line was also positive for IDH1R132 mutation and for ATRX. The results of characterization were summarized in table 1.

Publications & conference data

6 peer-reviewed publications reference this trial (live from Europe PMC):

1. The Sesquiterpene Lactone Cynaropicrin Manifests Strong Cytotoxicity in Glioblastoma Cells U-87 MG by Induction of Oxidative Stress.
   Rotondo R, Oliva MA, Arcella A. · · 2022 · cited 12× · PMID 35884887 · DOI 10.3390/biomedicines10071583
2. Characterization of primary glioma cell lines derived from the patients according to 2016 CNS tumour WHO classification and comparison with their parental tumours.
   Oliva MA, Staffieri S, Castaldo S, Giangaspero F, et al · · 2021 · cited 12× · PMID 33398536 · DOI 10.1007/s11060-020-03673-8
3. Cytotoxicity Effect of Quinoin, Type 1 Ribosome-Inactivating Protein from Quinoa Seeds, on Glioblastoma Cells.
   Rotondo R, Ragucci S, Castaldo S, Oliva MA, et al · · 2021 · cited 11× · PMID 34678977 · DOI 10.3390/toxins13100684
4. Functional Precision Oncology: The Next Frontier to Improve Glioblastoma Outcome?
   Panovska D, De Smet F. · · 2022 · cited 6× · PMID 35955765 · DOI 10.3390/ijms23158637
5. Aloe-Emodin Overcomes Anti-Cancer Drug Resistance to Temozolomide and Prevents Colony Formation and Migration in Primary Human Glioblastoma Cell Lines NULU and ZAR.
   Staffieri S, Russo V, Oliva MA, Alborghetti M, et al · · 2023 · cited 4× · PMID 37630276 · DOI 10.3390/molecules28166024
6. Ageritin-The Ribotoxin-like Protein from Poplar Mushroom (<i>Cyclocybe aegerita</i>) Sensitizes Primary Glioblastoma Cells to Conventional Temozolomide Chemotherapy.
   Rotondo R, Ragucci S, Castaldo S, Landi N, et al · · 2022 · cited 3× · PMID 35458581 · DOI 10.3390/molecules27082385